Stable Clear-Almost Clear Response is Sustained up to 3 Years in Patients with Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s599, 2025. DOI: 10.25251/y4a30r91. Disponível em: https://skin.dermsquared.com/skin/article/view/3832. Acesso em: 25 apr. 2026.